Feasibility study of nivolumab as neoadjuvant chemotherapy for locally esophageal carcinoma: FRONTiER (JCOG1804E)

Shun Yamamoto, Ken Kato, Hiroyuki Daiko, Takashi Kojima, Hiroki Hara, Tetsuya Abe, Yasuhiro Tsubosa, Kengo Nagashima, Kazunori Aoki, Yukihiro Mizoguchi, Shigehisa Kitano, Shinichi Yachida, Satoshi Shiba, Yuko Kitagawa

研究成果: Article

1 被引用数 (Scopus)

抄録

One of the standard treatments of resectable esophageal squamous cell carcinoma (ESCC) is neoadjuvant chemotherapy followed by surgery. Nivolumab showed efficacy for metastatic ESCC. However, the safety and efficacy of neoadjuvant nivolumab with chemotherapy for ESCC is unknown. Therefore, we will conduct FRONTiER to evaluate the safety and efficacy of nivolumab adding to neoadjuvant chemotherapy. FRONTiER comprises four experimental cohorts: (A) including nivolumab plus 5-FU+CDDP (cisplatin and 5-fluorouracil [CF]); (B) including one prior administration of nivolumab and the cohort A regimen; (C) including nivolumab plus docetaxel+ CF; (D) including one prior administration of nivolumab and the cohort C regimen; an expanded cohort. The primary end point is the incidence of dose-limiting toxicities from the initial dose to the 30th postoperative day. Clinical Trial Identifier: NCT0391444.

本文言語English
ページ(範囲)1351-1357
ページ数7
ジャーナルFuture Oncology
16
19
DOI
出版ステータスPublished - 2020 7

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

フィンガープリント 「Feasibility study of nivolumab as neoadjuvant chemotherapy for locally esophageal carcinoma: FRONTiER (JCOG1804E)」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル